Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
- PMID: 37406813
- DOI: 10.1016/j.annonc.2023.06.008
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
Conflict of interest statement
Disclosure UD has served as consultant/advisory board member for MSD, Pfizer, Bristol Myers Squibb, PharmaMar, Astellas, Janssen, Bayer, Ipsen, Eisai, Novartis, Roche, Clovis and AstraZeneca and received institutional research grants from AstraZeneca, Sanofi, and Roche. EFG received travel grant from Janssen. EV reported receiving honoraria for consulting or advisory role from Janssen, Ipsen, MSD, Merck, Pfizer, Novartis. GP has served as consultant/advisory board member for Astellas, AstraZeneca, Bayer, BMS, EISAI, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer. He received research grants from Astellas, Ipsen, and Novartis.
Comment on
-
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.Ann Oncol. 2023 Sep;34(9):772-782. doi: 10.1016/j.annonc.2023.06.009. Epub 2023 Jul 1. Ann Oncol. 2023. PMID: 37399894 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical